Zirconium-89 (89Zr)

Zirconium-89 is employed in specialized applications using positron emission tomography imaging, for example, with 89Zr-labeled antibodies (immuno-PET) [1][2][3].
Proteins and antibodies can be easily labelled with 89Zr using off-the-shelf chelates (visit: Macrocyclics, ABX), and subsequently applied in preclinical and clinical immuno-PET settings. Numerous antibodies have been labeled and evaluated, using immuno-PET to assess their potential [1][3].
We have been successfully producing GMP-compliant 89Zr for the research community since 2003 [2]. 89Zr is dispensed every week, and each batch of 89Zr is individually tested to ensure consistent quality. For further details on 89Zr, see our white paper as well as 89Zr training information.

Questions?
If you have any questions, do not hesitate to contact our development manager, Maria Vosjan. You can reach her at:
E-mail: m.vosjan@cyclotron.nl
Tel: +31 (0)20 4449141

   
  • Packaging: 2.0 mL V-bottom screw top glass vials.
  • Availability: Dispensed every Thursday.
  • Delivery Service: Cyclotron counts on its new cooperation partner PerkinElmer for distribution of the radionuclide 89Zr.

Decay table for Zirconium 89:

Fact Sheet: Zirconium-89Download



Process Data
Nuclear reaction Proton irradiation of natural yttrium-89
Assay Gamma-ray spectrometry: the most prominent gamma photon has an energy of 909 keV


Product Specification
Definition Zirconium-89 in 1 mol/L oxalic acid
Specific activity No carrier added
Activity concentration > 740 MBq/mL (20 mCi/mL)
Radionuclidic purity 89Zr ‚â• 99.9%
Others ≤ 0.1%
Tests pH: lower than 4
Endotoxin < 17.5 IU/mL


Where to buy
We rely on our partner PerkinElmer for distribution of Zirconium-89. To order this product, visit PerkinElmer's page on Zirconium-89.

Notes
(Click on the PMID to see abstracts from PubMed/NCBI)

[1] Van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010 Aug;25(4):375-85. PMID: 20707716.

[2] Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003 Aug;44(8):1271-81. PMID: 12902418.

[3] Perk LR, Vosjan MJWD, Visser GWM, et al. p-Isothiocyanatobenzyl-desferrioxamine: A new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010;37:250. PMID: 19763566.

Further reading suggestions
(Click on the PMID to see abstracts from PubMed/NCBI)

Aerts HJWL, Dubois L, Perk L, Vermaelen P, van Dongen GAMS, Wouters BG, Lambin P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009 Jan;50(1):123-31. PMID: 19091906.

Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA, van Dongen GA. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody \U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2133-40. PMID: 16609026.

Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GA, Boellaard R. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody \U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009 Nov;50(11):1828-36. PMID: 19837762.

Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010 May;87(5):586-92. PMID: 20357763.

Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, van Dongen GA, Oyen WJ, Boerman OC, Bussink J. PET of hypoxia with 89Zr-labeled cG250-F(ab‘)2 in head and neck tumors. J Nucl Med. 2010 Jul;51(7):1076-83. PMID: 20554724.

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010 Aug;51(8):1293-300. PMID: 20660376.

Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009 Oct;36(7):729-39. Epub 2009 Jul 29.PMID: 19720285.

Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging. 2010 Feb;9(1):1-20. PMID: 20128994.

McCabe KE, Wu AM. Positive progress in ImmunoPET – not just a coincidence. Cancer Biother Radiopharm. 2010 Jun;25(3):253-61. PMID: 20578830.

Nagengast WB, de Korte MA, Oude Munnink TH, TimmerBosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA, Lub-de Hooge MN, Schröder CP, de Vries EG. 89Zr-bevacizumab PET of early anti-angiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010 May;51(5):761-7. PMID: 20395337.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007 Aug;48(8):1313- 9. PMID: 17631557.

Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67. PMID: 18491091.

Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. p-Isothiocyanato- benzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):250-9. PMID: 19763566.

Tinianow JN, Gill HS, Ogas- awara A, Flores JE, Vanderbilt AN, Luis E, Vandlen R, Darwish M, Junutula JR, Williams SP, Marik J. Site-specifically 89Zr- labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol. 2010 Apr;37(3):289-97. PMID: 20346868.

van Dongen GAMS, Visser GWM, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navi- gator in monoclonal antibody development and applications. Oncologist. 2007 Dec;12(12):1379- 89. PMID: 18165614.

van Dongen GAMS, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010 Aug;25(4):375-85. PMID: 20707716.

Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: Comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003 Aug;44(8):1271-81. PMID: 12902418.

Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5(4):739-43. PMID: 20360768.

See also our special White Papers: "The Future of Immuno-PET in Drug Development: Zirconium-89 and Iodine-124 as Key Factors in Molecular Imaging."
Free download
and
"89Zr-Immuno-PET – Physical Properties, Production, Labeling and Applications of 89Zr"
Free download





BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, BV Cyclotron VU produces GMP-compliant medical isotopes in state-of-the-art manufacturing facilities. They are used daily by pharmaceutical and biotechnological companies, medical device manufacturers, hospitals, clinics, and research laboratories.
Order our products directly from one of our distribution partners.